Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Mark Breidenbach has maintained an Outperform rating on Nurix Therapeutics (NASDAQ:NRIX) and raised the price target from $27 to $30.
September 04, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reaffirmed its positive outlook on Nurix Therapeutics by maintaining an Outperform rating and increasing the price target to $30, indicating confidence in the company's future performance.
The increase in the price target from $27 to $30 by Oppenheimer suggests a positive outlook on Nurix Therapeutics' future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100